CD4+ T-cell receptor recognizing Human Papillomavirus L1 peptides presented on HLA class II (HPV L1-specific CD4+ TCR)

The CD4+ T-cell receptor (TCR) recognizing L1-derived peptides presented on HLA class II is a specialized immune receptor that mediates the recognition of the Human Papillomavirus (HPV) major capsid protein, L1. This interaction is fundamental to the efficacy of prophylactic HPV vaccines, such as Gardasil 9 and Cervarix, which utilize L1 virus-like particles (VLPs) to elicit a robust immune response (Source: National Cancer Institute). Upon vaccination or infection, antigen-presenting cells process the L1 protein and present its epitopes via HLA class II molecules, predominantly HLA-DR, to CD4+ T-helper cells (Source: PubMed PMID: 16439182). The subsequent activation of these T cells leads to the secretion of cytokines like interferon-gamma and interleukin-2, which are vital for the maturation of B cells into antibody-secreting plasma cells and the generation of long-term immunological memory (Source: Journal of Virology). While L1 expression is often lost during the progression of HPV-infected cells to invasive cancer, these TCRs remain a focus for understanding vaccine-induced protection and exploring therapeutic strategies for early-stage HPV-related lesions (Source: Nature Reviews Immunology). Safety considerations for therapies involving these TCRs include potential cross-reactivity with self-peptides and the risk of cytokine release syndrome in the context of adoptive cell transfer (Source: Molecular Therapy).

Other names

HPV L1-specific TCRMHC class II-restricted HPV L1 TCRCD4+ TCR for HPV capsid proteinHuman Papillomavirus L1-specific T-cell receptor

Recognition of specific HPV L1 peptide-HLA class II complexes by the TCR leads to the activation of CD4+ helper T cells, which coordinate the adaptive immune response through the secretion of Th1-type cytokines (e.g., IFN-gamma) and the stimulation of B-cells for neutralizing antibody production.